Thermo Fisher Scientific (NYSE:TMO) Releases Quarterly Earnings Results, Beats Estimates By $0.12 EPS

Thermo Fisher Scientific (NYSE:TMO) posted its quarterly earnings data on Thursday. The medical research company reported $6.57 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $6.45 by $0.12, FiscalAI reports. The business had revenue of $12.22 billion during the quarter, compared to the consensus estimate of $11.95 billion. Thermo Fisher Scientific had a return on equity of 16.92% and a net margin of 15.05%.Thermo Fisher Scientific’s quarterly revenue was up 7.2% on a year-over-year basis. During the same period last year, the company earned $6.10 earnings per share.

Here are the key takeaways from Thermo Fisher Scientific’s conference call:

• We delivered a strong finish to 2025 with Q4 revenue of $12.21B (+7%) and adjusted EPS of $6.57 (+8%), full?year revenue $44.56B (+4%) and adjusted EPS $22.87 (+5%), and we initiated 2026 guidance of $46.3B–$47.2B revenue and $24.22–$24.80 adjusted EPS (6%–8% growth, 3%–4% organic).
• Aggressive capital deployment — ~ $16.5B deployed in 2025 (including ~$13B for M&A and $3.6B returned to shareholders); the announced Clario acquisition (~$9B) is expected to close mid?2026 and be materially accretive to EPS.
• Product and partnership momentum — multiple high?impact launches (Orbitrap Astral Zoom, Krios 5 Cryo?TEM, Helios MX1, EXENT 510(k), expanded single?use bioreactors) and strategic collaborations (Chan Zuckerberg Institute, OpenAI) aim to deepen customer ties and embed AI across products and operations.
• Policy and macro risks remain — tariffs and FX volatility were >100 basis points of margin headwind in 2025 and the 2026 guide assumes current tariffs only, while China and U.S. academic/government funding weakness pressured some segments.

Thermo Fisher Scientific Stock Performance

NYSE:TMO opened at $578.20 on Friday. Thermo Fisher Scientific has a twelve month low of $385.46 and a twelve month high of $643.99. The company has a quick ratio of 1.11, a current ratio of 1.89 and a debt-to-equity ratio of 0.67. The stock’s 50-day simple moving average is $593.96 and its 200 day simple moving average is $537.07. The firm has a market capitalization of $217.24 billion, a PE ratio of 32.59, a price-to-earnings-growth ratio of 3.89 and a beta of 0.91.

Thermo Fisher Scientific Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Thursday, January 15th. Investors of record on Monday, December 15th were given a dividend of $0.43 per share. The ex-dividend date was Monday, December 15th. This represents a $1.72 annualized dividend and a dividend yield of 0.3%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is currently 9.94%.

Wall Street Analysts Forecast Growth

Several research firms have recently commented on TMO. Weiss Ratings reissued a “hold (c)” rating on shares of Thermo Fisher Scientific in a report on Friday, January 9th. Evercore ISI reiterated an “outperform” rating and issued a $650.00 price target on shares of Thermo Fisher Scientific in a research note on Monday, January 5th. Leerink Partners boosted their price objective on shares of Thermo Fisher Scientific from $545.00 to $580.00 and gave the stock an “outperform” rating in a research note on Wednesday, October 22nd. Citigroup lifted their price target on Thermo Fisher Scientific from $660.00 to $685.00 and gave the stock a “buy” rating in a report on Friday. Finally, Robert W. Baird set a $653.00 price objective on Thermo Fisher Scientific in a research note on Friday. One analyst has rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and three have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $633.68.

Insider Activity at Thermo Fisher Scientific

In other news, EVP Michael D. Shafer sold 10,725 shares of the company’s stock in a transaction on Tuesday, November 25th. The shares were sold at an average price of $600.00, for a total transaction of $6,435,000.00. Following the completion of the transaction, the executive vice president directly owned 18,731 shares in the company, valued at approximately $11,238,600. This represents a 36.41% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, VP Lisa P. Britt sold 10,225 shares of the business’s stock in a transaction dated Friday, November 7th. The stock was sold at an average price of $571.62, for a total value of $5,844,814.50. Following the sale, the vice president owned 14,145 shares in the company, valued at approximately $8,085,564.90. This trade represents a 41.96% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 124,517 shares of company stock worth $72,363,568 in the last 90 days. 0.33% of the stock is currently owned by company insiders.

Institutional Trading of Thermo Fisher Scientific

Large investors have recently bought and sold shares of the business. Brighton Jones LLC grew its holdings in Thermo Fisher Scientific by 28.9% during the fourth quarter. Brighton Jones LLC now owns 4,409 shares of the medical research company’s stock worth $2,293,000 after buying an additional 988 shares in the last quarter. Revolve Wealth Partners LLC grew its stake in Thermo Fisher Scientific by 4.2% in the 4th quarter. Revolve Wealth Partners LLC now owns 491 shares of the medical research company’s stock valued at $255,000 after purchasing an additional 20 shares during the period. Darwin Wealth Management LLC bought a new stake in shares of Thermo Fisher Scientific during the 2nd quarter worth $170,000. Raymond James Financial Inc. grew its position in Thermo Fisher Scientific by 7.4% during the second quarter. Raymond James Financial Inc. now owns 778,822 shares of the medical research company’s stock valued at $315,781,000 after buying an additional 53,542 shares during the period. Finally, California State Teachers Retirement System raised its position in Thermo Fisher Scientific by 0.4% in the second quarter. California State Teachers Retirement System now owns 602,031 shares of the medical research company’s stock worth $244,099,000 after acquiring an additional 2,262 shares during the period. 89.23% of the stock is currently owned by institutional investors and hedge funds.

Trending Headlines about Thermo Fisher Scientific

Here are the key news stories impacting Thermo Fisher Scientific this week:

• Positive Sentiment: Q4 results beat expectations — Adjusted EPS $6.57 and revenue $12.21B (?+7% YoY), driven by life-sciences tools and pharma demand; the print supports near-term organic growth narrative. Read More.
• Positive Sentiment: Analyst support remains — several firms reiterated buys/positive views and one bullish write-up called the pullback a buying opportunity, highlighting resilient margins and competitive positioning. Read More.
• Neutral Sentiment: 2026 guidance set in a narrow band — FY26 revenue guide $46.3B–$47.2B and EPS $24.22–$24.80, roughly around consensus but slightly below EPS midpoint; guidance implies modest 3%–4% organic growth and stabilizing demand. Read More.
• Negative Sentiment: Market reaction focused on cautious profit outlook and margin pressure — despite the beat, investors sold into the print due to conservative margin commentary and a guidance range that doesn’t accelerate growth significantly. Read More.
• Negative Sentiment: Analyst price-target trim — TD Cowen lowered its PT from $696 to $683 while keeping a Buy rating, signaling slightly reduced upside expectations even as coverage stays positive. Read More.

Thermo Fisher Scientific announced that its board has authorized a stock repurchase program on Thursday, November 6th that allows the company to buyback $5.00 billion in shares. This buyback authorization allows the medical research company to repurchase up to 2.4% of its stock through open market purchases. Stock buyback programs are typically a sign that the company’s board of directors believes its shares are undervalued.

About Thermo Fisher Scientific

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.